前沿生物与AFFiRiS宣布就靶向PCSK9的高胆固醇血症治疗药物AFFITOPE®AT04达成大中华区许可协议 前沿生物获得在大中华区开发与商业化AFFITOPE®AT04的独家权利合作旨在加快AFFITOPE®AT04主动免疫疗法作为同类首创新药的全球开发进程，推动其在大中华区的临床开发和生产落地 中国南京和奥地利维也纳, Dec. 22, 2021 (GLOBE NEWSWIRE) --...

AFFiRiS and Frontier Biotechnologies announce license agreement for AFFITOPE®AT04, an active immunotherapy targeting PCSK9 to treat hypercholesterolemia, in Greater China Frontier Biotechnologies obtains exclusive rights to develop and commercialize AFFITOPE® AT04 in Greater China Collaboration accelerates the global development of AFFiRiS potential first-in-class...

Cardiometabolic Diseases Market Size ($121,804.49Mn by 2028) Lead by Cardiovascular Disease (3.9% CAGR) Impact of Coronavirus Outbreak and Global Analysis & Forecast by TheInsightPartners.com New York, Oct. 29, 2021 (GLOBE NEWSWIRE) -- Cardiometabolic Diseases Market: Key InsightsAccording to our new research study on Cardiometabolic Diseases Market Size and Forecast to 2028 - COVID-19...

American Heart Association Comment: FDA Announces Safety Changes on Labeling for Some Statins DALLAS, Feb. 28, 2012 (GLOBE NEWSWIRE) -- The United States Food and Drug Administration (FDA) announced it is revising safety information on the labels of some statins (cholesterol lowering...